This technology is a specially formulated diet that can enhance the efficacy of standard cancer treatments.
For many cancer patients, chemotherapy and radiation treatments are met with limited success and cause harmful side effects. As such, there is a growing interest in shifting cancer therapeutics from cytotoxic, non-specific agents to highly-selective therapeutics, including advanced nutritional therapies. However, there is currently no defined nutritional formula that effectively targets cancer while sufficiently meeting the patient’s caloric needs.
This technology is a specialized diet for the enhancement of standard cancer treatment. The formula includes all of the necessary nutrients to fulfill energetic needs, but specifically omits two sulfur-containing amino acids. This diet is shown to selectively sensitize cancer cells to chemotherapy and radiation without causing deleterious systemic effects. As such, this technology has the potential to improve outcomes from first-line treatment strategies in patients with diverse types of cancer.
This technology has been validated in a mouse model of glioma.
Dominique Higgins, M.D., Ph.D.
Patent Pending
IR CU21118
Licensing Contact: Sara-Ann Gusik